Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab

R. Channa, R. Sophie, A. A. Khwaja, D. V. Do, G. Hafiz, Q. D. Nguyen, P. A. Campochiaro

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

PurposeTo identify factors associated with visual outcomes in patients with diabetic macular edema (DME) treated with ranibizumab (RBZ) in the Ranibizumab for Edema of the mAcula in Diabetes - Protocol 2 (READ-2) Study.Patients and methodsOptical coherence tomography scans, fundus photographs, and fluorescein angiograms (FAs) were graded and along with baseline characteristics were correlated with month (M) 24 visual outcome of best-corrected visual acuity (BCVA) ≤20/100 (poor outcome) vs >20/100 (better outcome).ResultsOf 101 patients with a M20 visit or beyond, 27 (27%) had BCVA ≤20/100. Comparison of patients with or without poor outcome showed mean baseline BCVA of 16.8 letters (20/125) in the former compared with 30.4 letters (20/63; P<0.001). Mean change in BCVA between baseline and M24 was -2.6 letters in the poor outcome group compared with +9.8 letters (P<0.001). Foveal thickness (FTH) at M24 was 374.1 μm in the poor outcome group compared with 268.8 μm (P<0.01), a difference driven by 14 patients with mean FTH of 450.3 μm. Foveal atrophy occurred in 65% (11/17) in the poor outcome group compared with 17%(12/71, P=0.001). Persistent edema was noted in 52% (14/27) of patients with poor outcome. Laser scars near foveal center were significantly more common in patients with poor outcome who did not have edema vs those who did (78% (7/9) vs 23% (3/13) P=0.03).ConclusionPoor baseline BCVA (≤20/125) in DME patients predicts poor visual outcome (≤20/100) after 2 years of treatment with RBZ and/or focal/grid laser, often due to foveal atrophy and/or persistent edema.

Original languageEnglish (US)
Pages (from-to)269-278
Number of pages10
JournalEye (Basingstoke)
Volume28
Issue number3
DOIs
StatePublished - Jan 1 2014

Fingerprint

Macular Edema
Visual Acuity
Edema
Atrophy
Lasers
Ranibizumab
Fluorescein
Cicatrix
Angiography
Tomography

Keywords

  • Anti-VEGF
  • Diabetic macular edema
  • Macular edema
  • Ranibizumab

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems

Cite this

Channa, R., Sophie, R., Khwaja, A. A., Do, D. V., Hafiz, G., Nguyen, Q. D., & Campochiaro, P. A. (2014). Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye (Basingstoke), 28(3), 269-278. https://doi.org/10.1038/eye.2013.245

Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. / Channa, R.; Sophie, R.; Khwaja, A. A.; Do, D. V.; Hafiz, G.; Nguyen, Q. D.; Campochiaro, P. A.

In: Eye (Basingstoke), Vol. 28, No. 3, 01.01.2014, p. 269-278.

Research output: Contribution to journalArticle

Channa, R, Sophie, R, Khwaja, AA, Do, DV, Hafiz, G, Nguyen, QD & Campochiaro, PA 2014, 'Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab', Eye (Basingstoke), vol. 28, no. 3, pp. 269-278. https://doi.org/10.1038/eye.2013.245
Channa, R. ; Sophie, R. ; Khwaja, A. A. ; Do, D. V. ; Hafiz, G. ; Nguyen, Q. D. ; Campochiaro, P. A. / Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. In: Eye (Basingstoke). 2014 ; Vol. 28, No. 3. pp. 269-278.
@article{f7d5c613ea4247d99b814d2f7560b36e,
title = "Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab",
abstract = "PurposeTo identify factors associated with visual outcomes in patients with diabetic macular edema (DME) treated with ranibizumab (RBZ) in the Ranibizumab for Edema of the mAcula in Diabetes - Protocol 2 (READ-2) Study.Patients and methodsOptical coherence tomography scans, fundus photographs, and fluorescein angiograms (FAs) were graded and along with baseline characteristics were correlated with month (M) 24 visual outcome of best-corrected visual acuity (BCVA) ≤20/100 (poor outcome) vs >20/100 (better outcome).ResultsOf 101 patients with a M20 visit or beyond, 27 (27{\%}) had BCVA ≤20/100. Comparison of patients with or without poor outcome showed mean baseline BCVA of 16.8 letters (20/125) in the former compared with 30.4 letters (20/63; P<0.001). Mean change in BCVA between baseline and M24 was -2.6 letters in the poor outcome group compared with +9.8 letters (P<0.001). Foveal thickness (FTH) at M24 was 374.1 μm in the poor outcome group compared with 268.8 μm (P<0.01), a difference driven by 14 patients with mean FTH of 450.3 μm. Foveal atrophy occurred in 65{\%} (11/17) in the poor outcome group compared with 17{\%}(12/71, P=0.001). Persistent edema was noted in 52{\%} (14/27) of patients with poor outcome. Laser scars near foveal center were significantly more common in patients with poor outcome who did not have edema vs those who did (78{\%} (7/9) vs 23{\%} (3/13) P=0.03).ConclusionPoor baseline BCVA (≤20/125) in DME patients predicts poor visual outcome (≤20/100) after 2 years of treatment with RBZ and/or focal/grid laser, often due to foveal atrophy and/or persistent edema.",
keywords = "Anti-VEGF, Diabetic macular edema, Macular edema, Ranibizumab",
author = "R. Channa and R. Sophie and Khwaja, {A. A.} and Do, {D. V.} and G. Hafiz and Nguyen, {Q. D.} and Campochiaro, {P. A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/eye.2013.245",
language = "English (US)",
volume = "28",
pages = "269--278",
journal = "Eye (London, England)",
issn = "0950-222X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab

AU - Channa, R.

AU - Sophie, R.

AU - Khwaja, A. A.

AU - Do, D. V.

AU - Hafiz, G.

AU - Nguyen, Q. D.

AU - Campochiaro, P. A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - PurposeTo identify factors associated with visual outcomes in patients with diabetic macular edema (DME) treated with ranibizumab (RBZ) in the Ranibizumab for Edema of the mAcula in Diabetes - Protocol 2 (READ-2) Study.Patients and methodsOptical coherence tomography scans, fundus photographs, and fluorescein angiograms (FAs) were graded and along with baseline characteristics were correlated with month (M) 24 visual outcome of best-corrected visual acuity (BCVA) ≤20/100 (poor outcome) vs >20/100 (better outcome).ResultsOf 101 patients with a M20 visit or beyond, 27 (27%) had BCVA ≤20/100. Comparison of patients with or without poor outcome showed mean baseline BCVA of 16.8 letters (20/125) in the former compared with 30.4 letters (20/63; P<0.001). Mean change in BCVA between baseline and M24 was -2.6 letters in the poor outcome group compared with +9.8 letters (P<0.001). Foveal thickness (FTH) at M24 was 374.1 μm in the poor outcome group compared with 268.8 μm (P<0.01), a difference driven by 14 patients with mean FTH of 450.3 μm. Foveal atrophy occurred in 65% (11/17) in the poor outcome group compared with 17%(12/71, P=0.001). Persistent edema was noted in 52% (14/27) of patients with poor outcome. Laser scars near foveal center were significantly more common in patients with poor outcome who did not have edema vs those who did (78% (7/9) vs 23% (3/13) P=0.03).ConclusionPoor baseline BCVA (≤20/125) in DME patients predicts poor visual outcome (≤20/100) after 2 years of treatment with RBZ and/or focal/grid laser, often due to foveal atrophy and/or persistent edema.

AB - PurposeTo identify factors associated with visual outcomes in patients with diabetic macular edema (DME) treated with ranibizumab (RBZ) in the Ranibizumab for Edema of the mAcula in Diabetes - Protocol 2 (READ-2) Study.Patients and methodsOptical coherence tomography scans, fundus photographs, and fluorescein angiograms (FAs) were graded and along with baseline characteristics were correlated with month (M) 24 visual outcome of best-corrected visual acuity (BCVA) ≤20/100 (poor outcome) vs >20/100 (better outcome).ResultsOf 101 patients with a M20 visit or beyond, 27 (27%) had BCVA ≤20/100. Comparison of patients with or without poor outcome showed mean baseline BCVA of 16.8 letters (20/125) in the former compared with 30.4 letters (20/63; P<0.001). Mean change in BCVA between baseline and M24 was -2.6 letters in the poor outcome group compared with +9.8 letters (P<0.001). Foveal thickness (FTH) at M24 was 374.1 μm in the poor outcome group compared with 268.8 μm (P<0.01), a difference driven by 14 patients with mean FTH of 450.3 μm. Foveal atrophy occurred in 65% (11/17) in the poor outcome group compared with 17%(12/71, P=0.001). Persistent edema was noted in 52% (14/27) of patients with poor outcome. Laser scars near foveal center were significantly more common in patients with poor outcome who did not have edema vs those who did (78% (7/9) vs 23% (3/13) P=0.03).ConclusionPoor baseline BCVA (≤20/125) in DME patients predicts poor visual outcome (≤20/100) after 2 years of treatment with RBZ and/or focal/grid laser, often due to foveal atrophy and/or persistent edema.

KW - Anti-VEGF

KW - Diabetic macular edema

KW - Macular edema

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=84896356110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896356110&partnerID=8YFLogxK

U2 - 10.1038/eye.2013.245

DO - 10.1038/eye.2013.245

M3 - Article

VL - 28

SP - 269

EP - 278

JO - Eye (London, England)

JF - Eye (London, England)

SN - 0950-222X

IS - 3

ER -